HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.

AbstractAIM:
To assess the efficacy and safety of an intravitreal injection of bevacizumab (Avastin(R)) for myopic choroidal neovascularisation (mCNV).
METHODS:
Intravitreal bevacizumab (1 mg) was injected into eight eyes of eight patients with mCNV in this non-randomised, interventional case series. The best-corrected visual acuity (BCVA) was measured and the optical coherence tomography (OCT) and fluorescein angiography findings were examined before and after treatment. The minimum follow-up time was 3 months.
RESULTS:
The mean BCVA was 0.26 before treatment and 0.51 at the last visit (p = 0.009). The BCVA improved to two or more lines in six eyes (75%) and remained the same in two eyes (25%). Leakage from the mCNV on fluorescein angiography decreased in seven eyes (87.5%). The choroidal neovascularisation area on fluorescein angiography (p = 0.049) and the foveal thickness on OCT images decreased significantly (p = 0.027) after the treatment. No major complications developed.
CONCLUSION:
Intravitreal injection of bevacizumab seems to be an effective and safe treatment for mCNV.
AuthorsH Sakaguchi, Y Ikuno, F Gomi, M Kamei, M Sawa, M Tsujikawa, Y Oshima, S Kusaka, Y Tano
JournalThe British journal of ophthalmology (Br J Ophthalmol) Vol. 91 Issue 2 Pg. 161-5 (Feb 2007) ISSN: 0007-1161 [Print] England
PMID16914470 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
Topics
  • Adult
  • Aged
  • Angiogenesis Inhibitors (administration & dosage, therapeutic use)
  • Antibodies, Monoclonal (administration & dosage, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Choroidal Neovascularization (drug therapy, etiology, pathology, physiopathology)
  • Female
  • Follow-Up Studies
  • Fovea Centralis (pathology)
  • Humans
  • Male
  • Middle Aged
  • Myopia, Degenerative (complications)
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)
  • Visual Acuity (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: